Aim: The aim of the present study was to determine the demographic characteristics, localization of emboli, imaging findings, National Institutes of Health Stroke Scale (NIHSS) scores, and complications of patients who received intravenous (iv) tissue plasminogen activator (t-PA) due to early period of ischemic cerebrovascular disease (CVD) during the 6-year period in a tertiary level emergency department of a university hospital.
Introduction
Cerebrovascular disease (CVD) is a syndrome that occurs with the sudden deterioration of blood flow in the blood vessels of the brain (1) . Thromboembolic events or occlusions result in ischemic strokes and constitute approximately 70%-80% of total stroke cases (2) . It is the second most common cause of death worldwide, followed by cardiovascular diseases in the 60 years or older population. In addition, it is the major cause of disability and labor loss (3, 4) . In Turkey, cardiovascular diseases are the leading cause of death with a rate of 21.7% and CVDs in second place with 15% (5).
Thrombolytic therapy with tissue plasminogen activator (t-PA) gives clinically much better results than other treatment options in the early phase (first 3 h) of ischemic CVD (6) . Intravenous (iv) t-PA administration was approved by the Food and Drug Administration in 1996 and was considered as the most promising treatment method in the first 3 h of ischemic CVD in 2012 (3, 7) . Although it has clinically better results, iv t-PA therapy has a potential risk for intracerebral hemorrhage (3) . Thrombolytic therapy is also frequently used by emergency physicians because patients are usually admitted to the emergency departments (EDs) in the early stage of CVD. However, owing to the risk of intracerebral hemorrhage, emergency physicians are often hesitant to apply this treatment.
Magnetic resonance imaging (MRI) shows the brain tissue better than computed tomography (CT) in patients admitted to the ED with clinical suspicion of CVD (6) . It has also been reported that MRI with diffusion-weighted images and perfusion sequences may be helpful in identifying patients who will receive more benefit from t-PA therapy (8) .
The aim of the present study was to determine the demographic characteristics, localization, imaging findings, National Institutes of Health Stroke Scale (NIHSS) scores, and complications of patients who received iv t-PA due to early period of ischemic CVD during the 6-year period in a tertiary level ED of a university hospital.
Materials and Methods
The present study was retrospectively performed in 65 patients aged ≥18 years and who underwent iv t-PA with a diagnosis of ischemic CVD in a tertiary level ED of a university hospital for 6 years. The local ethics committee (Erciyes University Ethical Committee of Clinical Researches, Date: 21.03.2014, Decision Number: 2014/172) approved the study. Patients who received iv t-PA for urgent septicemia during the last 6 years with the help of the hospital registration system were identified.
Inclusion criteria for patients with ischemic stroke who had been able to acquire t-PA remedy within 4.5 h after the disease onset were as follows: (1) diagnosis of acute ischemic stroke, (2) measurable neurological deficits, and (3) symptom onset within 3-4.5 h before remedy. Exclusion criteria included (1) blood pressure that cannot be lowered safely to <185/110 mmHg with antihypertensive agents; (2) history of intracranial hemorrhage (this does not include cerebral microhemorrhages); (3) platelets<100,000, international normalized ratio>1.7, activated partial thromboplastin time (aPTT)>40 s, or prothrombin time>15 s; (4) use of therapeutic or prophylactic dose low-molecular-weight heparin within 24 h or any unfractionated heparin use associated with an elevated aPTT; (5) use of direct thrombin inhibitors (dabigatran) or factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban) within 48 h; (6) patients with a structural gastrointestinal (GI) malignancy or GI bleeding within 21 days; (7) ischemic stroke and symptoms consistent with infective endocarditis; (8) known or suspected aortic dissection; (9) intracranial or intraspinal surgery within the last 3 months; and (10) intra-axial intracranial neoplasm (extra-axial intracranial neoplasm is not a contraindication).
Cranial CT and diffusion MRI were used for diagnostic imaging of the patients. Patient files and t-PA application forms were used to access patient information.
Demographic data such as age, sex, smoking, use of anticoagulation and/or antiaggregant drugs, and chronic illness were obtained by examining the medical records of the patients. The baseline Glasgow Coma Scale (GCS), NIHSS, start time of the event, time of admission to the hospital, blood parameters, application time of t-PA, presence or absence of secondary hemorrhagic complications due to t-PA, and prognosis of the patients were recorded on the study form. Mortality rates due to intracranial hemorrhage during hospital stay of the patient after t-PA admission were also recorded on the study form.
Complication Outcome
Exist, n (%) Not exist, n (%) p Exitus, n (%) Discharged, n (%) p 
Statistical analysis
The duration of t-PA therapy applied to the patient, time of admission, NIHSS scores, age of the patients, and relationship between intracerebral hemorrhage complication and mortality were assessed by independent t-test. The chi-square test was used to evaluate the relationship among the radiological findings of patients, time interval of t-PA treatment applied to the patient, anticoagulant/antiaggregant agent, and cigarette use.
Results
Sixty-five patients who met the study criteria were included in the study. The mean age of the patients was 66.2 years (min-max: 24-79 years), and 46.2% (n=30) of the patients were men and 53.8% (n:35) of the patients were women. Table 1 shows the demographic data such as comorbid diseases, anticoagulant/antiaggregant drug use, and GCS scores.
Cranial CT scan was performed in all of the patients, and 78.5% of the patients had no acute pathological findings. It was observed that diffusion MRI was not performed in 41.5% of the patients, and middle cerebral artery infarction was detected in 23.1% of the patients with diffusion MRI performed. Table 2 shows the cranial imaging results of the patients.
When the times in which patients receive thrombolytic therapy are examined, the highest rate was found with 46.2%, in the period of 16:00-00:00. The average time interval between event occurrence and hospital arrival was 70±39 min, the average time interval between the time of arrival to the hospital and the time of application of t-PA treatment was 59±24 min, and the average time interval between the time of occurrence of the event and the time of application of t-PA was 130±41 min.
Hemorrhagic complications were detected in 16.9% of the patients after treatment, and all of these complications were intracranial hemorrhage. On examination of the patients' outcome, 1.5% (n=1) of the patients died in the ED, and 20 of 21) patients died in the intensive care unit. The mortality rate of the patients who received t-PA therapy in the ED was lower than that in the other departments where patients transferred. However, we hypothesized that it would be related to the short duration time of the patients in the ED compared with other departments. Hemorrhagic complications were present after t-PA admission in 6 out of a total of 21 patients who died. In order to evaluate the most common administration time of t-PA in the ED, we have evaluated three shifts. Further, it has been found that it is most commonly used in the period between 16:00 and 0:00 h. Table 3 shows the patients' time for t-PA administration, complications, and outcome patterns.
The baseline NIHSS and GCS scores were assessed to evaluate the neurological status of the patients and were found to be 11.4±4.3 and 13±2.1 points, respectively.
While no significant relationship was found between the initiation time of t-PA treatment and complication development, a significant correlation was found between high NIHSS score and complication development and mortality. Table 4 shows these values.
No significant association was found between smoking, anticoagulant/ antiaggregant drug use, time to administration of t-PA treatment, and complication development or mortality. Table 5 shows these findings.
Discussion
It was found that 23% (n=7) of male patients and 40% (n=14) of female patients who were included in the study died. According to the records of the Ministry of Health of Turkey regarding death rates due to CVD, 15.5% were men and 15.7% were women. This rate increases to 20.8% in men and 20.2% in women over 60 years old in urban areas (5). In our study, mortality rates were found to be higher (32.3%) than country rates. We think that the high mortality rate is due to the fact that our hospital is a university hospital, and we usually treat patients with high comorbidity. Although the same t-PA protocol was applied to all of the patients, the mortality rates in the ED were lower than those in the other departments. We think that it could be related to the duration time of the patients because the duration time of the patients in the ED was short. Most of them were transferred to the other departments after admission of iv t-PA.
There was no significant relationship between the initiation time of t-PA treatment and the complication of intracerebral hemorrhage in our study. This result is consistent with previous studies showing the efficacy and safety of initiation of t-PA therapy within the first 4.5 h (9). While it is stated in the literature that there is a significant relationship between the time of initiation of treatment and mortality (10), it has been observed that the initiation of treatment in any period within the first 4.5 h in our study does not affect mortality (11) . This suggests that starting treatment at any time within the first 4.5 h will not affect mortality.
There was no significant association between smoking, anticoagulant/ antiaggregant drug use, time to administration of t-PA treatment, and complication development or mortality. We believe that these results are satisfactory for t-PA use, since it shows that patients with these clinical conditions are not under increased risk of intracranial complications, and t-PA could be used for such patients safely.
In the literature, it was stated that an NIHSS score of ≥8 at the time of admission indicates increased risk of intracerebral hemorrhage and mortality (3). In our study, the NIHSS scores of all patients who developed complications or died were ≥8. This suggests that the high NIHSS score of the patient at the time of admission would alert the emergency physician of complications and mortality.
It has been reported in literature that high blood glucose levels are associated with increased intracerebral hemorrhage risk in patients receiving t-PA (3). A previous study reported that a pretreatment blood glucose level of >200 mg/dL is a high risk factor for intracerebral hemorrhage alone (12) . However, in our study, the average blood glucose level of patients with complications was 157 mg/dL. This suggests that high blood glucose level alone is not responsible in terms of risk of developing intracerebral hemorrhage in patients receiving t-PA due to CVD.
It has been determined that the only factor that poses an independent risk for both parenchymal hematomas and intracerebral hemorrhage (12) . Despite the risk of intracerebral hemorrhage, there are studies showing the benefit of iv t-PA in elderly patients (13) (14) (15) (16) . In our study, the mean age of the patients with complications was 66.9±1.5 years, whereas the mean age of the patients without complications was 66.3±1.2 years. This finding was not consistent with the literature, and there was no significant relationship between age and complication (p>0.05). This suggests that other comorbid conditions, in addition to age, are also related to the development of complications. There was no significant correlation between age and mortality (p>0.05), which was consistent with the literature. For this reason, we believe that when the decision to use iv t-PA is made, especially in elderly patients, not only the risks but also the benefits must be kept in mind.
Study limitations
The major limitation of the present study is that it is performed in a single center. In addition, the study population was limited, and studies conducted with larger populations are needed. Another limitation of the present study is that the duration time of admission to the ED and t-PA treatment starting time of all of the patients are not the same.
Conclusion
In our study, it has been seen that the high NIHSS score at the time of admission increases both the risk of intracerebral hemorrhagic complication and mortality. While a correlation between the age of the elderly and the development of intracerebral hemorrhagic complications was reported in literature reviews, there was no significant relationship found in the present study. We hypothesize that iv t-PA treatment gives successful results despite the complications in emergency patients with CVD, and emergency physicians should be more courageous in their application especially in elderly patients.
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